Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

mobile phones

- PMLiVE

FDA advisors back Novo Nordisk’s IDeglira combination

Unanimous vote is a step forward for the Tesiba-Victoza injection

National Institute for Health and Care Excellence NICE logo

NICE backs freer use of SGLT2 inhibitors for diabetes

Recommendation positions Invokana, Forxiga and Jardiance as first-line treatments

- PMLiVE

Merck drops once-weekly diabetes drug in US and EU

Says decision is due to “business reasons” not safety or efficacy issues

AstraZeneca AZ

AstraZeneca launches diabetes lifestyle campaign

Aims to support people with type 2 diabetes in becoming more active

- PMLiVE

Diabetes: Let’s cut the Gordian knot by Debashis Bhattacharya and Kamlesh Sheth

Digital health specialists Aegleio suggest that a culture change is needed to cope with the rise of diabetes in the UK.

Say Communications

- PMLiVE

Roche integrates diabetes app with Apple Health

Accu-Chek Connect will allow patients to share data with the iPhone system

- PMLiVE

Abbott diabetes sensor wins European CE mark

FreeStyle Libre system gains kitemark

- PMLiVE

Merck and Sun Pharma part company on branded generics

Will continue partnership on diabetes and inflammatory disorder projects

- PMLiVE

Tresiba safer than insulin glargine, says Novo Nordisk

Trial compares its basal insulin with Sanofi's Lantus

Eli Lilly HQ

Lilly’s Lantus ‘follow-on’ approved in the US

Basaglar is first insulin product to be licensed via the FDA's truncated 505(b)(2) pathway

- PMLiVE

Novo Nordisk will work with IBM on diabetes care

Development of digital platform to help diabetics and their doctors manage their illness

Eli Lilly HQ

Lilly says insulin peglispro too risky to pursue

Discontinues development of medicine once tipped as a diabetes blockbuster

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links